Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry.
Buckstein R, Chodirker L, Mozessohn L, Yee KWL, Geddes M, Zhu N, Shamy A, Leitch HA, Christou G, Banerji V, Brian L, Khalaf D, St-Hilaire E, Finn N, Nevill T, Keating MM, Storring J, Delage R, Parmentier A, Thambipillai A, Siddiqui M, Westcott C, Cameron C, Mamedov A, Spin P, Tang D. Buckstein R, et al. Among authors: mamedov a. Leuk Lymphoma. 2022 Dec;63(13):3165-3174. doi: 10.1080/10428194.2022.2109154. Epub 2022 Sep 12. Leuk Lymphoma. 2022. PMID: 36095125
Initial transfusion intensity predicts survival in myelodysplastic syndrome.
Chan LS, Shapiro R, Buckstein R, Lin Y, Callum J, Chodirker L, Lee CD, Prica A, Lam A, Mamedov A, Wells RA. Chan LS, et al. Among authors: mamedov a. Leuk Lymphoma. 2014 Oct;55(10):2296-300. doi: 10.3109/10428194.2013.878934. Epub 2014 Feb 24. Leuk Lymphoma. 2014. PMID: 24397595
Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis.
Buckstein R, Kerbel R, Cheung M, Shaked Y, Chodirker L, Lee CR, Lenis M, Davidson C, Cussen MA, Reis M, Chesney A, Zhang L, Mamedov A, Wells RA. Buckstein R, et al. Among authors: mamedov a. Leuk Res. 2014 Jul;38(7):756-63. doi: 10.1016/j.leukres.2014.03.022. Epub 2014 Apr 5. Leuk Res. 2014. PMID: 24819395 Free article. Clinical Trial.
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Leitch HA, Parmar A, Wells RA, Chodirker L, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating MM, Sabloff M, St Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Kew A, Shamy A, Elemary M, Lenis M, Mamedov A, Ivo J, Francis J, Zhang L, Buckstein R. Leitch HA, et al. Among authors: mamedov a. Br J Haematol. 2017 Oct;179(1):83-97. doi: 10.1111/bjh.14825. Epub 2017 Jul 5. Br J Haematol. 2017. PMID: 28677895 Free article.
Revised 15-item MDS-specific frailty scale maintains prognostic potential.
Wan BA, Nazha A, Starkman R, Alibhai S, Wells RA, Geddes M, Zhu N, Keating MM, Leber B, Chodirker L, Sabloff M, Christou G, Leitch HA, St-Hilaire E, Finn N, Shamy A, Yee KWL, Storring J, Nevill TJ, Delage R, Elemary M, Banerji V, Parmentier A, Siddiqui M, Kirubananthaan A, Mamedov A, Zhang L, Buckstein R. Wan BA, et al. Among authors: mamedov a. Leukemia. 2020 Dec;34(12):3434-3438. doi: 10.1038/s41375-020-01026-y. Epub 2020 Aug 28. Leukemia. 2020. PMID: 32855438 No abstract available.
Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study.
Amitai I, Geddes M, Zhu N, Keating MM, Sabloff M, Christou G, Leber B, Khalaf D, Leitch HA, St-Hilaire E, Finn N, Shamy A, Yee K, Storring J, Nevill T, Delage R, Elemary M, Banerji V, Chodirker L, Mozessohn L, Parmentier A, Siddiqui M, Mamedov A, Zhang L, Buckstein R. Amitai I, et al. Among authors: mamedov a. Br J Haematol. 2021 Jul;194(2):319-324. doi: 10.1111/bjh.17537. Epub 2021 May 31. Br J Haematol. 2021. PMID: 34060069
The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes.
Brailovski E, Li Q, Liu N, Leber B, Khalaf D, Sabloff M, Christou G, Yee K, Chodirker L, Parmentier A, Siddiqui M, Mamedov A, Zhang L, Liu Y, Earle CC, Cheung MC, Mittmann N, Buckstein RJ, Mozessohn L. Brailovski E, et al. Among authors: mamedov a. Ann Hematol. 2022 May;101(5):1023-1030. doi: 10.1007/s00277-022-04802-1. Epub 2022 Feb 22. Ann Hematol. 2022. PMID: 35190844
A machine learning model of response to hypomethylating agents in myelodysplastic syndromes.
Radakovich N, Sallman DA, Buckstein R, Brunner A, Dezern A, Mukerjee S, Komrokji R, Al-Ali N, Shreve J, Rouphail Y, Parmentier A, Mamedov A, Siddiqui M, Guan Y, Kuzmanovic T, Hasipek M, Jha B, Maciejewski JP, Sekeres MA, Nazha A. Radakovich N, et al. Among authors: mamedov a. iScience. 2022 Aug 12;25(10):104931. doi: 10.1016/j.isci.2022.104931. eCollection 2022 Oct 21. iScience. 2022. PMID: 36157589 Free PMC article.
Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes.
Mozessohn L, Li Q, Liu N, Leber B, Khalaf D, Sabloff M, Christou G, Yee K, Chodirker L, Parmentier A, Siddiqui M, Mamedov A, Zhang L, Liu Y, Earle CC, Cheung MC, Mittmann N, Buckstein R. Mozessohn L, et al. Among authors: mamedov a. JCO Oncol Pract. 2023 Apr;19(4):e559-e569. doi: 10.1200/OP.22.00668. Epub 2023 Feb 10. JCO Oncol Pract. 2023. PMID: 36763927 Free PMC article.
206 results